Full Press Release Details
Vesting of awards under the Long Term Incentive Plan
London: Wednesday, March 29, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announces that following the publication of the 2016 annual report of Chi-Med on March 27, 2017, the following awards granted under the Long Term Incentive Plan ( LTIP ) on October 19, 2015 in respect of the annual performance targets for the financial year 2014 to Mr. Christian Hogg, Mr. Johnny Cheng and Dr. Weiguo Su were vested on March 28, 2017:-
| Award Holders | Number of Ordinary Shares | Number of American depositary shares ( ADS ) | |
| Person Discharging Managerial Responsibilities | |||
| Mr. Christian Hogg (Executive Director and Chief Executive Officer) | 5,620 | 3,756 | |
| Mr. Johnny Cheng (Executive Director and Chief Financial Officer) | Nil | 4,626 | |
| Dr. Weiguo Su (Executive Director and Chief Scientific Officer) | Nil | 5,476 | |
| Total | 5,620 | 13,858 |
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Mr Christian Hogg | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Director and Chief Executive Officer | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Hutchison China MediTech Limited | |||
| b) | LEI | N/A | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of US$1.00 each ADS each representing one half of one Ordinary Share of US$1.00 | |||
| Identification code | DI ISIN: KYG4672N1016 ADS ISIN: US44842L1035 | ||||
| b) | Nature of the transaction | Vesting of awards granted on October 19, 2015 in respect of the annual performance targets for the financial year 2014 under Chi-Med's LTIP | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| Nil | 5,620 Ordinary Shares | ||||
| Nil | 3,756 ADS | ||||
| d) | Aggregated information | N/A | |||
| Aggregated volume | |||||
| Price | |||||
| e) | Date of the transaction | 2017-03-28 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) / Nasdaq Stock Market |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Mr Johnny Cheng | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Director and Chief Financial Officer | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Hutchison China MediTech Limited | |||
| b) | LEI | N/A | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | ADS each representing one half of one Ordinary Share of US$1.00 | |||
| Identification code | ADS ISIN: US44842L1035 | ||||
| b) | Nature of the transaction | Vesting of awards granted on October 19, 2015 in respect of the annual performance targets for the financial year 2014 under Chi-Med's LTIP | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| Nil | 4,626 ADS | ||||
| d) | Aggregated information | N/A | |||
| Aggregated volume | |||||
| Price | |||||
| e) | Date of the transaction | 2017-03-28 | |||
| f) | Place of the transaction | Nasdaq Stock Market |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Dr Weiguo Su | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Director and Chief Scientific Officer | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Hutchison China MediTech Limited | |||
| b) | LEI | N/A | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | ADS each representing one half of one Ordinary Share of US$1.00 | |||
| Identification code | ADS ISIN: US44842L1035 | ||||
| b) | Nature of the transaction | Vesting of awards granted on October 19, 2015 in respect of the annual performance targets for the financial year 2014 under Chi-Med's LTIP | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| Nil | 5,476 ADS | ||||
| d) | Aggregated information | N/A | |||
| Aggregated volume | |||||
| Price | |||||
| e) | Date of the transaction | 2017-03-28 | |||
| f) | Place of the transaction | Nasdaq Stock Market |
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
| Investor Enquiries | ||
| Christian Hogg, CEO | +852 2121 8200 | |
| U.K. and International Media Enquiries | ||
| Anthony Carlisle, Citigate Dewe Rogerson | +44 7973 611 888 (Mobile) | anthony.carlisle@cdrconsultancy.co.uk |
| U.S. Based Media Enquiries | ||
| Brad Miles, BMC Communications | +1 (917) 570 7340 (Mobile) | bmiles@bmccommunications.com |
| Susan Duffy, BMC Communications | +1 (917) 499 8887 (Mobile) | sduffy@bmccommunications.com |
| Investor Relations | ||
| Matt Beck, The Trout Group | +1 (917) 415 1750 (Mobile) | mbeck@troutgroup.com |
| David Dible, Citigate Dewe Rogerson | +44 7967 566 919 (Mobile) | david.dible@citigatedr.co.uk |
| Panmure Gordon (UK) Limited | ||
| Richard Gray / Andrew Potts | +44 (20) 7886 2500 |